Dr. David Lovejoy visited JCBI on July 11. During this period, he had in-depth communication with te

News

PhD Student Travel Grant was awarded to Yilin Deng and Tianran Chai

PhD candidate Hyungjoon Kwon of National Cancer Center of Korea visited JCBI

Dr. Rowan Radford from Macquarie University visited our center on 31st July and shared his valuable experience in confoc

Happy news: another research paper of our center has been successfully accepted for publication on Advanced Materials

Dr. David Lovejoy visited JCBI on July 11. During this period, he had in-depth communication with teachers and students

2019.06.10 Dr. Marco Morsch visited the International Joint Centre for Biomedical Innovation（JCBI）

Dr. Shu Yang visited our center on 31st May and presented her research about “Confocal Microscopy”, shared her valuable

Henan University announced its launching ceremony for its Centre for Aggregation-Induced Emission Nanobionics Research

WILEY-Henan University International Nanobionics Symposium was held in Kaifeng

Dr. Wenya He’s postdoctoral opening report was held in our center

2019.03.14 Dr. SHI Bingyang visited his old school.

2019.02.21 Dr. SHI Bingyang and his team published new research paper on Angewandte Chemie International Edition.

2018.09.18. Dr. SHI Bingyang and his team published new research paper on Advanc

Dr. David Lovejoy visited JCBI on July 11. During this period, he had in-depth communication with teachers and students

Dr. David Lovejoy visited JCBI

Dr. David Lovejoy visited JCBI on July 11. During this period, he had in-depth communication with teachers and students from JCBI and shared his years of research experience. Then, he visited the experiment and instrument platform of

JCBI.

Dr. David Lovejoy has been engaged in research on medical chemistry and biomedical. By far, he has more than 50 publications in top ranked internationalresearch journals including Blood, Cancer Research etc. He has led or participated in more than 30 scientific research projects and was accredited 2 patents. Dr. David Lovejoy also equipped with extensive experience in the application of scientific research results. The cancer treatment molecule: DpC, which was designed and synthesized by Lovejoy himself, has engaged in phase 1 clinical trials. In addition, Dr. David Lovejoy founded Oncochel Therapeutics LLC (USA), a company dedicated to translating scientific research in biomedical related fields into social benefits.